Skip to main content

Summit Therapeutics Inc.

SMMT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001599298

No open-market purchases or sales by Summit Therapeutics Inc. insiders were filed in the last 90 days; 242 institutions reported holding it in 13F filings for Q2 2026, worth $1.98B in total; no superinvestor holds it.

Holders of 5% or more of SMMT

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Summit Therapeutics Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Summit Therapeutics Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on Summit Therapeutics Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on SMMT
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 14, 2022Polar Capital Holdings Plc13G/AOld format–––SEC
May 14, 2021Duggan Robert W13D/AOld format–––SEC
Apr 22, 2021Duggan Robert W13D/AOld format–––SEC
Mar 26, 2021Duggan Robert W13D/AOld format–––SEC
Feb 16, 2021Polar Capital Holdings Plc13GOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Summit Therapeutics Inc. shares.

No Form 144 notices for Summit Therapeutics Inc. are on file.